Stock Track | Moderna Plummets Over 5% as Trump Administration Plans to Cut Vaccine Aid Support

Stock Track03-26

Shares of Moderna, Inc. (MRNA) plummeted 5.08% during Wednesday's trading session, significantly underperforming the broader market. The biotech company, known for its mRNA vaccine technology, faced a sharp selloff as investors reacted to concerning news in the vaccine industry.

The stock's decline appears to be directly linked to reports that the Trump Administration plans to end support for Gavi, a global vaccine alliance. This decision could potentially impact the demand for vaccines, including those produced by Moderna. The news has sent shockwaves through the vaccine market, with other companies like Novavax also experiencing declines.

This development raises questions about the future of vaccine distribution and support, particularly in developing countries where Gavi plays a crucial role. For Moderna, which has been a key player in the COVID-19 vaccine market, the potential reduction in vaccine aid could signal challenges ahead for its global distribution efforts and possibly impact its revenue projections.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1117005787?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-26 23:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1117005787","market":"us","top_or_hot":-1,"title":"Stock Track | Moderna Plummets Over 5% as Trump Administration Plans to Cut Vaccine Aid Support","media":"Stock Track","content":"<p>Shares of Moderna, Inc. (MRNA) plummeted 5.08% during Wednesday's trading session, significantly underperforming the broader market. The biotech company, known for its mRNA vaccine technology, faced a sharp selloff as investors reacted to concerning news in the vaccine industry.</p>\n\n<p>The stock's decline appears to be directly linked to reports that the Trump Administration plans to end support for Gavi, a global vaccine alliance. This decision could potentially impact the demand for vaccines, including those produced by Moderna. The news has sent shockwaves through the vaccine market, with other companies like Novavax also experiencing declines.</p>\n\n<p>This development raises questions about the future of vaccine distribution and support, particularly in developing countries where Gavi plays a crucial role. For Moderna, which has been a key player in the COVID-19 vaccine market, the potential reduction in vaccine aid could signal challenges ahead for its global distribution efforts and possibly impact its revenue projections.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Moderna Plummets Over 5% as Trump Administration Plans to Cut Vaccine Aid Support</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Moderna Plummets Over 5% as Trump Administration Plans to Cut Vaccine Aid Support\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-03-26 23:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Moderna, Inc. (MRNA) plummeted 5.08% during Wednesday's trading session, significantly underperforming the broader market. The biotech company, known for its mRNA vaccine technology, faced a sharp selloff as investors reacted to concerning news in the vaccine industry.</p>\n\n<p>The stock's decline appears to be directly linked to reports that the Trump Administration plans to end support for Gavi, a global vaccine alliance. This decision could potentially impact the demand for vaccines, including those produced by Moderna. The news has sent shockwaves through the vaccine market, with other companies like Novavax also experiencing declines.</p>\n\n<p>This development raises questions about the future of vaccine distribution and support, particularly in developing countries where Gavi plays a crucial role. For Moderna, which has been a key player in the COVID-19 vaccine market, the potential reduction in vaccine aid could signal challenges ahead for its global distribution efforts and possibly impact its revenue projections.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRNA","symbol_name":"Moderna, Inc.","start_time":0,"source_url":"","article_id":"1117005787","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1117005787","pubTimestamp":1743002447,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Moderna, Inc.  plummeted 5.08% during Wednesday's trading session, significantly underperforming the broader market. The biotech company, known for its mRNA vaccine technology, faced a sharp selloff as investors reacted to concerning news in the vaccine industry.The stock's decline appears to be directly linked to reports that the Trump Administration plans to end support for Gavi, a global vaccine alliance. This decision could potentially impact the demand for vaccines, including thos","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRNA":"Moderna, Inc."},"translate_title":"特朗普政府计划削减疫苗援助支持Moderna股价暴跌超5%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNA":1},"content_text":"Shares of Moderna, Inc. (MRNA) plummeted 5.08% during Wednesday's trading session, significantly underperforming the broader market. The biotech company, known for its mRNA vaccine technology, faced a sharp selloff as investors reacted to concerning news in the vaccine industry.\nThe stock's decline appears to be directly linked to reports that the Trump Administration plans to end support for Gavi, a global vaccine alliance. This decision could potentially impact the demand for vaccines, including those produced by Moderna. The news has sent shockwaves through the vaccine market, with other companies like Novavax also experiencing declines.\nThis development raises questions about the future of vaccine distribution and support, particularly in developing countries where Gavi plays a crucial role. For Moderna, which has been a key player in the COVID-19 vaccine market, the potential reduction in vaccine aid could signal challenges ahead for its global distribution efforts and possibly impact its revenue projections.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1117005787","isCrawlerRequest":true}